DF/HCC Kidney Cancer SPORE

DF/HCC 肾癌孢子

• 批准号: 10024137
• 负责人: WILLIAM G. KAELIN
• 金额: $ 254.32万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-18 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10024137
• 关键词: Address; Basic Science; Biological; Biometry; Boston; Cancer Biology; Cancer Center; Center Core Grants; Clear Cell; Clinical; Clinical Data; Clinical Research; Combined Modality Therapy; Communities; Complex; Computational Biology; Critical Pathways; Dana-Farber Cancer Institute; Development; Device or Instrument Development; Evaluation; Funding; Future; General Hospitals; Genomics; Goals; Grant; Hospitals; Immunocompetent; Incentives; Infrastructure; Institution; Israel; Kidney Neoplasms; Knowledge; Laboratory Scientists; Malignant Neoplasms; Massachusetts; Medical center; Mentors; Mission; Molecular; Monitor; Mutate; New Agents; Oncogenic; Outcome; Pathology; Pathway interactions; Patients; Pediatric Hospitals; Physicians; Program Development; Progress Reports; Public Health Schools; Renal carcinoma; Reporting; Research Personnel; Resistance; Scientist; Seasons; Specialized Program of Research Excellence; Stream; Talents; Technology; Testing; Time; Tissues; Toxic effect; Translational Research; Treatment outcome; Woman; advanced disease; anticancer research; base; career; career development; clinical application; clinical investigation; community center; drug development; effective therapy; immune checkpoint; interest; medical schools; molecular marker; mouse model; novel; patient population; predicting response; predictive marker; programmed cell death protein 1; programs; resistance mechanism; standard care; success; tool; translational scientist

Summary This application represents a resubmission of a competing renewal application for a Specialized Program of Research Excellence (SPORE) in Kidney Cancer from the Kidney Cancer Program of Dana-Farber/Harvard Cancer Center (DF/HCC). The DF/HCC Kidney Cancer SPORE has been funded for two cycles since 2003. DF/HCC is comprised of the following institutions: Beth Israel-Deaconess Medical Center (BIDMC); Dana- Farber Cancer Institute (DFCI); Harvard Medical School; Harvard School of Public Health; Brigham and Women’s Hospital; Massachusetts General Hospital (MGH); and Children’s Hospital of Boston. In addition to the institutions in the DF/HCC, the Georgetown-Lombardi Cancer Center (GLCC) is collaborating institutions in this grant. The DF/HCC Kidney Cancer SPORE has its administrative base at the BIDMC. Dr. David McDermott, who has led the DF/HCC Kidney Cancer Program and SPORE since 2012 is joined as SPORE Director by Dr. William Kaelin, a laboratory scientist at DFCI and has served with Dr. McDermott as Director of the SPORE since early 2014. Dr. Kaelin is a world renowned basic and translational investigator with longstanding interest in renal cancer and a leader within the DF/HCC community. Drs. McDermott and Kaelin report directly to Dr. Laurie Glimcher, Director of DF/HCC and President of DFCI. The DF/HCC Kidney Cancer SPORE has a broad and deep talent base and there is extensive institutional commitment. We take advantage of a large patient population and cutting edge technologies that are available to us as part of DF/HCC. We propose 3 Projects which address critical problems in kidney cancer and have translational components. They focus on identifying effective strategies for targeting: HIF2α, the dominant oncogenic driver of clear-cell RCC (Project 1), resistance mechanisms of standard therapies (Projects 2-3, DRP 17), novel immune checkpoint pathways (Project 3) and rare kidney tumor types (e.g. NF2 mutated and translocation RCC, DRP 18 and 17). The projects are supported by three Cores - an Administrative Core, a Biostatistics and Computational Biology Core, and a Tissue Acquisition, Pathology and Clinical Data Core. We also have a highly successful Career Development Program that selects talented physician scientists and mentors them to independence as well as a Developmental Projects Program that generates new ideas for the SPORE in the future. The existence of the SPORE has provided opportunities and incentives to extend basic science and clinical research ideas into the translational realm and facilitated the entry of young, as well as some seasoned, investigators into the kidney cancer field where they have made major contributions.

总结 此申请代表重新提交的专业课程的竞争性续期申请， 来自Dana-Farber/哈佛肾癌项目的肾癌卓越研究（SPORE） 癌症中心（DF/HCC）。DF/HCC肾癌孢子自2003年以来已资助了两个周期。 DF/HCC由以下机构组成：贝斯以色列女执事医疗中心（BIDMC）;达纳- 法伯癌症研究所（DFCI）;哈佛医学院;哈佛公共卫生学院;布里格姆和 妇女医院、马萨诸塞州总医院和波士顿儿童医院。除了 DF/HCC的机构，乔治敦-隆巴迪癌症中心（GLCC）是合作机构 在这份赠款中。DF/HCC肾癌孢子在BIDMC有其行政基础。大卫医生 McDermott自2012年以来一直领导DF/HCC肾癌项目和SPORE， 主任由DFCI实验室科学家William Kaelin博士担任，并与McDermott博士一起担任主任 自2014年初以来，Kaelin博士是世界知名的基础和翻译研究者， 长期以来一直对肾癌感兴趣，是DF/HCC社区的领导者。麦克德莫特医生和凯林医生 直接向DF/HCC主任和DFCI总裁劳里·格利姆彻博士报告。DF/HCC肾脏 Cancer SPORE拥有广泛而深厚的人才基础，并有广泛的机构承诺。我们采取 我们拥有庞大的患者群体和尖端技术的优势， DF/HCC。我们提出了3个项目，这些项目解决了肾癌的关键问题， 件.他们专注于确定有效的靶向策略：HIF 2 α，主要的致癌基因， 透明细胞RCC的驱动因素（项目1），标准疗法的耐药机制（项目2-3，DRP 17）， 新的免疫检查点途径（项目3）和罕见的肾脏肿瘤类型（例如NF 2突变和 易位RCC，DRP 18和17）。这些项目由三个核心支持，即行政核心、 生物统计学和计算生物学核心，以及组织采集，病理学和临床数据核心。 我们还有一个非常成功的职业发展计划，选择有才华的医生科学家， 指导他们独立，以及发展项目计划，产生新的想法， 未来的孢子。SPORE的存在提供了机会和激励， 基础科学和临床研究理念进入转化领域，并促进了年轻人的进入，以及 作为一些经验丰富的研究人员，他们在肾癌领域做出了重大贡献。